Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Foviscu vs Meropenem in Complicated UTI or Acute Pyelonephritis
NCT03630081Phase 3Not yet recruiting
- Sponsor
- Wockhardt
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of Foviscu in complicated urinary tract infection (cUTI) and acute pyelonephritis (2 arms), sponsored by Wockhardt. Primary endpoints: Percentage of subjects with overall success at Day 5, Percentage of subjects with overall success at Test-of-Cure at Day 17 and 1 more. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
Foviscu
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on NCT03630081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03630081.